Home Cart Sign in  
Chemical Structure| 844442-38-2 Chemical Structure| 844442-38-2

Structure of AT7519
CAS No.: 844442-38-2

Chemical Structure| 844442-38-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AT7519 is a pan-CDKs inhibitor with IC50 values of 47, 13, <10nM for CDK2/CyclinA, CDK5/p35 and CDK9/CyclinT, and modest activity against CDK1/CyclinB, CDK3/CyclinE, CDK4/CyclinD1 and CDK6/CyclinD3 with IC50 values of 210, 360, 100 and 170nM, respectively.

Synonyms: AT7519M

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AT7519

CAS No. :844442-38-2
Formula : C16H17Cl2N5O2
M.W : 382.24
SMILES Code : O=C(C1=NNC=C1NC(C2=C(Cl)C=CC=C2Cl)=O)NC3CCNCC3
Synonyms :
AT7519M
MDL No. :MFCD13184820

Safety of AT7519

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of AT7519

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK5

    CDK5/p35, IC50:13 nM

  • CDK4

    CDK4/CyclinD1, IC50:100 nM

  • CDK2

    CDK2/CyclinA, IC50:47 nM

  • CDK6

    CDK6/CyclinD3, IC50:170 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01652144 Mantle Cell Lymphoma PHASE2 COMPLETED 2015-02-13 CancerCare Manitoba, Winnipeg,... More >> Manitoba, R3E 0V9, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|McGill University - Dept. Oncology, Montreal, Quebec, H2W 1S6, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada Less <<
NCT01627054 Chronic Lymphocytic Leukemia PHASE2 COMPLETED 2015-02-13 CancerCare Manitoba, Winnipeg,... More >> Manitoba, R3E 0V9, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.62mL

0.52mL

0.26mL

13.08mL

2.62mL

1.31mL

26.16mL

5.23mL

2.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories